Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (1-10 of 153) with videos related to

Pageof 16
Sort By:
Leukemia|August 29, 2019
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript typeMichele Baccarani, Gianantonio Rosti, Simona Soverini
Nature Reviews. Clinical Oncology|November 3, 2016
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Annals of Hematology|March 28, 2015
A review of the European LeukemiaNet recommendations for the management of CMLMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Seminars in Hematology|February 4, 2003
Interferon-alfa for chronic myeloid leukemiaMichele Baccarani, Domenico Russo, Gianantonio Rosti, et al.
Seminars in Hematology|June 5, 2003
The cytogenetic response as a surrogate marker of survivalGianantonio Rosti, Nicoletta Testoni, Giovanni Martinelli, et al.
Current Hematologic Malignancy Reports|January 8, 2014
Molecular monitoringSimona Soverini, Gianantonio Rosti, Michele Baccarani, et al.
Haematologica|April 12, 2005
New tyrosine kinase inhibitors in chronic myeloid leukemiaGiovanni Martinelli, Simona Soverini, Gianantonio Rosti, et al.
Critical Reviews in Oncology/Hematology|May 14, 2011
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phaseGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Frontiers in Oncology|April 2, 2021
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseFausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, et al.
Cancer Treatment Reviews|August 16, 2011
Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CMLGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Pageof 16

Showing results (1-10 of 153) with videos related to

Sort By:
Pageof 16
Leukemia|August 29, 2019
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript typeMichele Baccarani, Gianantonio Rosti, Simona Soverini
Nature Reviews. Clinical Oncology|November 3, 2016
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Annals of Hematology|March 28, 2015
A review of the European LeukemiaNet recommendations for the management of CMLMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Seminars in Hematology|February 4, 2003
Interferon-alfa for chronic myeloid leukemiaMichele Baccarani, Domenico Russo, Gianantonio Rosti, et al.
Seminars in Hematology|June 5, 2003
The cytogenetic response as a surrogate marker of survivalGianantonio Rosti, Nicoletta Testoni, Giovanni Martinelli, et al.
Current Hematologic Malignancy Reports|January 8, 2014
Molecular monitoringSimona Soverini, Gianantonio Rosti, Michele Baccarani, et al.
Haematologica|April 12, 2005
New tyrosine kinase inhibitors in chronic myeloid leukemiaGiovanni Martinelli, Simona Soverini, Gianantonio Rosti, et al.
Critical Reviews in Oncology/Hematology|May 14, 2011
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phaseGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Frontiers in Oncology|April 2, 2021
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseFausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, et al.
Cancer Treatment Reviews|August 16, 2011
Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CMLGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Pageof 16